1. Revenues for the quarter stood at ₹3,345.9 as against ₹2146.4 Cr in Q3FY21, translating growth of 55.9% YoY
2. EBITDA margins stood at 25.7%
Revenue breakup
Chemical business-42.6%, Packaging films-38.1%, Technical textile- 16.1% and others-3.2%
Business Highlights
1. Launched new pharma intermediate during the quarter and successfully conducted campaigns for 2-3 upcoming products.
2. Achieved highest ever production in key products and are constantly enhancing capacity utilisation at newly commissioned facility
3. Intent to keep debt at similar levels
4. The new pharma plant will follow CGMP but are not tested yet, but largely all new plants are following that approach
5. SRF share for HFC in domestic market is 60-70% and for non-HFC it will probably be in 40-50%
6. The cycle for renewal of contracts begins in Q1 and Q2 next year
7. The volumes have gone up substantially in the US markets
Chemical
1. Segment delivered healthy performance during the period owing to incremental revenues, expansion in product portfolio and increased focus on cost of production
2. Fluorochemicals Business delivered robust performance on the account of higher prices of certain key refrigerant products in critical international markets, Increased export volumes of HFC blends and chloromethanes.
3. Capex in chemicals:Pharma Intermediates plant (PIP) at a cost of ₹190 crore; to strengthen SRF’s pharma capabilities. The new pharma plant is designed to make 2-3 different products.
4. Dedicated facility of a key agrochemical product at a cost of ₹61 crore
5. Expecting demand for refrigerant to stay healthy in the upcoming quarter with HST and R32 gaining momentum and likely to expand further.
6. Refrigerant gas demand is higher in Q4 and expect the Q4 to perform better than last year
Packaging film business
1. Business performed very well, with both the domestic and international facilities delivering robust results.
2. Volume growth owing to additional capacities in Hungary and Thailand coming on stream. Margins pressure could be anticipated as few line will come onstream in coming quarters
Higher margins witnessed in BOPP segment
Technical textile business
1. Despite weak demand for nylon triangle fabrics, textile performed well driven by volumes in belting fabrics and industrial polyester yarn segment
2. The polyester yarn segment achieved best ever results amidst challenging market situation
3. Due to slow demand in tyre or OEM industry, nylon segment is impacted by lower volumes and high input costs affecting the margins profile for the company
4. The company is constantly focusing on cost improvement and efficiency
Capex
1. SRF is investing in the aluminium foil segment to create business adjacencies keeping in mind growth as a core strategy, at a new site in Jaitapur, Indore, India at an approximate cost of ₹425 crore
2. The plant is expected to commercialise in next 20 months i.e. around Sep-Oct 2023
2. Asset turn will range from 1.75-2X
3. Total capex for the year is ₹1900-2000 Cr of which:
₹1600- ₹1700 Cr to be spent on ongoing projects, additionally ₹400- ₹500 Cr capex will get sanctioned during FY23. So FY23 capex will range in ₹2100- ₹2200 Cr
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. Revenues for the quarter stood at ₹2376 Cr, with a robust growth of 100.1% YoY
2. Both the Pharmaceuticals & Specialty Chemicals segment outperformed during the quarter
3. Revenue expansion during the quarter includes cost escalations passed on to the customers due to substantial increase in raw material prices as well as fuel and logistics costs
4. Accrual of termination fees in respect of the long-term contract of ₹631 crores resulting in higher revenues. As a result, EBITDA includes ₹611 Crs during the quarter.
1. Revenues from operations stood at Rs. 396.6 crore in Q3FY22 as against Rs. 375.4 crore in Q3FY21, higher by 5.6%
2. EBITDA margins remained stable on a sequential basis at 15.8% translating to EBITDA of 63.8 crore
3. Gross margins in 9M FY22 stood at 41.4%
4. Q3 FY22 revenues growth was driven on the back of rebound in consumer demand led by discretionary items and new client wins.
5. While the domestic core fragrance segment delivered healthy performance, sales in Southeast Asia region continued to be affected by the Covid surge and is yet to recover
1. Revenues for the quarter stood at ₹6002 Cr (1% decline YoY).
2. EBITDA was at ₹1016 Cr (20% decline YoY) for the quarter. EBITDA margins for the quarter were 16.9%. PAT stood at ₹604.3 Cr (80% decline YoY).
3. Revenue from formulations was ₹4992 Cr (12% decline YoY).
4. Formulations contributed about 83% of total revenues. Revenue from the API business stood at ₹1010 Cr (48% growth YoY) and contributed about 17% of revenues.
1. Revenues are flat and profitability is down because of the high base effect.
2. Q3 and Q4 of FY21 were phenomenal quarters for the company because there was a major poultry disease outbreak which led to increased demand for vaccines.
3. They also have additional income every year from licensing fees which is not there in Q3 FY22.
4. They have been working on 3 vaccines - classical swine fever, lumpy skin disease and sheep pox vaccine. All these vaccines are in the final stages of quality testing and regulatory approval and they hope to launch them in Q1 FY23.